Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

References

• Ries LAG, Melbert D, Krapcho M, . editors. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute, Bethesda, MD. Based on November 2006 SEER data submission, posted to the SEER web site, 2007. Available from: http://seercancergov/csr/1975_2004/
   Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Hallek M, Wanders L, Ostwald M, . Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996;22:439–447.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh AA, Widhopf G, . Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639–1647.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343: 1910–1916.
   PubMed Web of Science ®Google Scholar
• Mayr C, Speicher MR, Kofler DM, . Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742–751.
   PubMed Web of Science ®Google Scholar
• Johnson S, Smith AG, Loffler H, . Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996;347:1432–1438.
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, . Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–1757.
   PubMed Web of Science ®Google Scholar
• Leporrier M, Chevret S, Cazin B, . Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319–2325.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M, . Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, . Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011;29:1349–1355.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA, . Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6–14.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, . Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–3561.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, . Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378–4384.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, . Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1 - 2 study. Blood 2008;111:1094–1100.
   PubMed Web of Science ®Google Scholar
• Matutes E, Owusu-Ankomah K, Morilla R, . The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640–1645.
   PubMed Web of Science ®Google Scholar
• Pu QQ, Bezwoda WR. Interleukin-4 prevents spontaneous in-vitro apoptosis in chronic lymphatic leukaemia but sensitizes B-CLL cells to melphalan cytotoxicity. Br J Haematol 1997;98:413–417.
   PubMed Web of Science ®Google Scholar
• Francia di Celle P, Mariani S, Riera L, . Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood 1996;87:4382–4389.
   PubMed Web of Science ®Google Scholar
• Moreno A, Villar ML, Camara C, . Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells. Blood 2001;97:242–249.
   PubMed Web of Science ®Google Scholar
• Jurlander J, Lai CF, Tan J, . Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood 1997;89:4146–4152.
   PubMed Web of Science ®Google Scholar
• Trentin L, Cerutti A, Zambello R, . Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 1996;87:3327–3335.
   PubMed Web of Science ®Google Scholar
• de Totero D, Meazza R, Capaia M, . The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood 2008;111:517–524.
   PubMed Web of Science ®Google Scholar
• Trentin L, Zambello R, Agostini C, . Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. Blood 1993;81:752–758.
   PubMed Web of Science ®Google Scholar
• Digel W, Stefanic M, Schoniger W, . Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 1989;73:1242–1246.
   PubMed Web of Science ®Google Scholar
• Nishio M, Endo T, Tsukada N, . Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005;106:1012–1020.
   PubMed Web of Science ®Google Scholar
• Endo T, Nishio M, Enzler T, . BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007;109:703–710.
   PubMed Web of Science ®Google Scholar
• Enzler T, Kater AP, Zhang W, . Chronic lymphocytic leukemia of E{micro}-TCL1 transgenic mice undergoes rapid cell-turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009;114:4469–4476.
   PubMed Web of Science ®Google Scholar
• Haiat S, Billard C, Quiney C, . Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006;118: 281–292.
   PubMed Web of Science ®Google Scholar
• Kern C, Cornuel JF, Billard C, . Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679–688.
   PubMed Web of Science ®Google Scholar
• Furman RR, Asgary Z, Mascarenhas JO, . Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200–2206.
   PubMed Web of Science ®Google Scholar
• Kitada S, Zapata JM, Andreeff M, . Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;106:995–1004.
   PubMed Web of Science ®Google Scholar
• Clayton E, Bardi G, Bell SE, . A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002;196:753–763.
   PubMed Web of Science ®Google Scholar
• Cuni S, Perez-Aciego P, Perez-Chacon G, . A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004;18:1391–1400.
   PubMed Web of Science ®Google Scholar
• Romano MF, Lamberti A, Tassone P, . Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998;92:990–995.
   PubMed Web of Science ®Google Scholar
• Luqman M, Klabunde S, Lin K, . The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112:711–720.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, . National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990–4997.
   PubMed Web of Science ®Google Scholar
• Vosters O, Beuneu C, Nagy N, . CD40 expression on human pancreatic duct cells: role in nuclear factor-kappa B activation and production of pro-inflammatory cytokines. Diabetologia 2004;47: 660–668.
   PubMed Web of Science ®Google Scholar
• Klein D, Barbe-Tuana F, Pugliese A, . A functional CD40 receptor is expressed in pancreatic beta cells. Diabetologia 2005;48: 268–276.
   PubMed Web of Science ®Google Scholar
• Advani R, Forero-Torres A, Furman RR, . Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009;27: 4371–4377.
   PubMed Web of Science ®Google Scholar
• Furman RR, Forero-Torres A, Shustov A, . A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51:228–235.
   PubMed Web of Science ®Google Scholar
• Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984;63: 305–309.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Gowda A, Joshi T, . The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 2009;144:848–855.
   PubMed Web of Science ®Google Scholar